VIR Q1 2024 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M-10.5% YoY

Gross Profit

-$42M-74.8% margin

Operating Income

-$80M-142.0% margin

Net Income

-$65M-115.8% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

+235.8%

Cash Flow

Operating Cash Flow

-$109M

Free Cash Flow

-$111M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$247M

Stockholders' Equity

$1.5B

Cash & Equivalents

$161M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$63M	-10.5%
Gross Profit	-$42M	-$97M	+56.4%
Operating Income	-$80M	-$143M	+44.1%
Net Income	-$65M	-$141M	+53.7%

Revenue Segments

Contract Revenue

$52M91%

Grant

$5M9%